Biogen (BIIB) is testing support at its 10-week line, giving investors a chance to buy shares of one of the top stocks in the highest-ranked industry group. But is it a good idea to buy now? This is the second test of the key support line since Biogen cleared a 347.85 buy point of a consolidation in December.